[Use of etofyllinclofibrate (Duolip Forte) in combined hyperlipidemia].

Abstract

BACKGROUND:

Duolip forte (ethophyllinclofibrate) is a lipid lowering drug, the effect of which was not yet adequately verified in our conditions, namely from the point of its effect on various types of hyperlipoproteinaemias.

METHOD AND RESULTS:

The therapy was applied on 45 patients with combined hyperlipidaemia, 25 men and 20 women, mean age 53.8 years (age range 41-65). About one half of patients were treated for hypertension, almost one quart of them manifested ischemic heart disease, 13% had a history of myocardial infarction and the same percentage suffered from associated diabetes type 2. Duolip forte was administered perorally in a dose of 500 mg once daily for 12-16 weeks to the patients who had complied with the prescribed diet (weight loss, improvement of lipid levels) during three-month preliminary period, but did not reach desirable parameters. After the therapy, the whole group studied manifested a significant decrease of total cholesterol (-10.8%), LDL-cholesterol (-13%), triglycerides (-40.8%) and free fatty acids (-20.6%), while the increase of HDL-cholesterol and its fractions was not significant. In hyperlipoproteinaemias of IIa type (n = 15), only a significant decrease of LDL-cholesterol appeared, in hyperlipoproteinaemias of IIb type (n = 15), a significant decrease was evidenced only in triglycerides (-33.9%). In hyperlipoproteineaemias of IV type (n = 15), a significant decrease was observed in triglycerides (-50.3%), while HDL-2 cholesterol values increased (+32.3%). A slight decrease of uric acid level and of body mass index observed in all groups was statistically not significant, as well as a slight increase of glycaemia and changes of serum transaminases. No unwanted side effects of Duolip were found.

CONCLUSIONS:

Ethophyllinclofibrate has proved as effective namely at hypertriglyceridemic primary hyperlipidaemias. Besides decreasing triglycerides, it increases significantly HDL-2 cholesterol. A convenient dosage, small lithogenic effect and minimum of side effects make it a drug of choice for some groups of elderly high-risk patients.

• Authors: J Hrebícek, N Skottová, Z Chmela, M Hrbková
• Journal: Casopis lekaru ceskych (Cas Lek Cesk) Vol. 134 Issue 5 Pg. 141-4 (Mar 08 1995) ISSN: 0008-7335 [Print] Czech Republic
• Vernacular Title: Zkusenosti s aplikací etofylinklofibrátu (Duolip forte) u kombinovaných hyperlipidémií.
• PMID: 7728839 (Publication Type: English Abstract, Journal Article)

Chemical References

• Hypolipidemic Agents
• Lipids
• etofylline clofibrate
• Clofibrate

Topics

• Adult
• Aged
• Clofibrate (analogs & derivatives, therapeutic use)
• Female
• Humans
• Hyperlipoproteinemia Type II (blood, drug therapy)
• Hyperlipoproteinemia Type V (blood, drug therapy)
• Hypolipidemic Agents (therapeutic use)
• Lipids (blood)
• Male
• Middle Aged